Reported Earnings • May 14
First quarter 2026 earnings released: NT$0.33 loss per share (vs NT$0.038 profit in 1Q 2025) First quarter 2026 results: NT$0.33 loss per share (down from NT$0.038 profit in 1Q 2025). Revenue: NT$147.4m (up 10% from 1Q 2025). Net loss: NT$12.7m (down NT$14.1m from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Annuncio • Mar 17
Medimaging Integrated Solution Inc., Annual General Meeting, Jun 23, 2026 Medimaging Integrated Solution Inc., Annual General Meeting, Jun 23, 2026, at 09:00 Taipei Standard Time. Location: 2 floor no,1, kung yeh tung 2nd rd., hsinchu city Taiwan Reported Earnings • Mar 17
Full year 2025 earnings released: EPS: NT$0.20 (vs NT$0.15 in FY 2024) Full year 2025 results: EPS: NT$0.20 (up from NT$0.15 in FY 2024). Revenue: NT$661.4m (up 23% from FY 2024). Net income: NT$7.73m (up 38% from FY 2024). Profit margin: 1.2% (up from 1.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. New Risk • Mar 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.07b (US$96.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Market cap is less than US$100m (NT$3.07b market cap, or US$96.9m). Annuncio • Dec 20
Medimaging Integrated Solution Inc. has filed a Follow-on Equity Offering in the amount of TWD 134.4 million. Medimaging Integrated Solution Inc. has filed a Follow-on Equity Offering in the amount of TWD 134.4 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,000,000
Price\Range: TWD 67.2
Transaction Features: Rights Offering Annuncio • Dec 19
Medimaging Integrated Solution Inc. announced that it has received TWD 201 million in funding Medimaging Integrated Solution Inc. announced a private placement of 2nd domestic unsecured convertible bonds for gross proceeds of TWD 201,000,000 on December 18, 2025. The transaction has been approved by the board of directors of the company. Reported Earnings • Nov 13
Third quarter 2025 earnings released: EPS: NT$0.06 (vs NT$0.59 loss in 3Q 2024) Third quarter 2025 results: EPS: NT$0.06 (up from NT$0.59 loss in 3Q 2024). Revenue: NT$152.8m (up 47% from 3Q 2024). Net income: NT$2.16m (up NT$24.8m from 3Q 2024). Profit margin: 1.4% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$0.85 loss per share (vs NT$0.069 profit in 2Q 2024) Second quarter 2025 results: NT$0.85 loss per share (down from NT$0.069 profit in 2Q 2024). Revenue: NT$154.6m (up 26% from 2Q 2024). Net loss: NT$29.6m (down NT$32.0m from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Upcoming Dividend • Aug 12
Upcoming dividend of NT$0.50 per share Eligible shareholders must have bought the stock before 19 August 2025. Payment date: 19 September 2025. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 0.6%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (3.6%). Annuncio • Jun 20
Medimaging Integrated Solution Inc. Appoints Fan, Ching Yi as New Accounting Officer Medimaging Integrated Solution Inc. appointed FAN, CHING YI as Deputy Director of the Finance & Accounting Effective date: June 19, 2025. Approved by the Compensation Committee, Audit Committee, and Board of Directors on June 19, 2025. Annuncio • May 30
Mi iS Receives EU MDR Clearance Forsingle-Use Cystoscope Medimaging Integrated Solution Inc. announced that MiiS received EU MDR clearance for single-use cystoscope. The single-use flexible cystoscope is a sterile, single-use, and flexible device intended to be operated with its compatible display system. The device provides endoscopic procedure and surgical treatment within the lower urinary tract. For examination or auxiliary treatment, the tissue structure of the lower urinary tract can be photographed, and real-time images can be provided for medical professional to evaluate tissue damage or disease. Reported Earnings • May 14
First quarter 2025 earnings released: EPS: NT$0.04 (vs NT$0.30 loss in 1Q 2024) First quarter 2025 results: EPS: NT$0.04 (up from NT$0.30 loss in 1Q 2024). Revenue: NT$133.7m (up 38% from 1Q 2024). Net income: NT$1.44m (up NT$11.7m from 1Q 2024). Profit margin: 1.1% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Annuncio • May 06
Medimaging Integrated Solution Inc. to Report Q1, 2025 Results on May 13, 2025 Medimaging Integrated Solution Inc. announced that they will report Q1, 2025 results on May 13, 2025 Reported Earnings • Apr 02
Full year 2024 earnings released: EPS: NT$0.16 (vs NT$2.20 in FY 2023) Full year 2024 results: EPS: NT$0.16 (down from NT$2.20 in FY 2023). Revenue: NT$538.9m (flat on FY 2023). Net income: NT$5.61m (down 92% from FY 2023). Profit margin: 1.0% (down from 14% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Annuncio • Mar 05
Medimaging Integrated Solution Inc. to Report Fiscal Year 2024 Results on Mar 12, 2025 Medimaging Integrated Solution Inc. announced that they will report fiscal year 2024 results on Mar 12, 2025 Reported Earnings • Nov 18
Third quarter 2024 earnings released: NT$0.65 loss per share (vs NT$0.50 profit in 3Q 2023) Third quarter 2024 results: NT$0.65 loss per share (down from NT$0.50 profit in 3Q 2023). Revenue: NT$104.1m (down 15% from 3Q 2023). Net loss: NT$22.7m (down 236% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Annuncio • Nov 01
Medimaging Integrated Solution Inc. to Report Q3, 2024 Results on Nov 08, 2024 Medimaging Integrated Solution Inc. announced that they will report Q3, 2024 results on Nov 08, 2024 Reported Earnings • Aug 18
Second quarter 2024 earnings released: EPS: NT$0.07 (vs NT$0.86 in 2Q 2023) Second quarter 2024 results: EPS: NT$0.07 (down from NT$0.86 in 2Q 2023). Revenue: NT$122.5m (down 14% from 2Q 2023). Net income: NT$2.38m (down 92% from 2Q 2023). Profit margin: 1.9% (down from 20% in 2Q 2023). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Annuncio • Aug 02
Medimaging Integrated Solution Inc. to Report Q2, 2024 Results on Aug 09, 2024 Medimaging Integrated Solution Inc. announced that they will report Q2, 2024 results on Aug 09, 2024 Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to NT$97.10, the stock trades at a trailing P/E ratio of 66.1x. Average trailing P/E is 22x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 85% over the past three years. Declared Dividend • Jun 27
Dividend increased to NT$1.80 Dividend of NT$1.80 is 0.2% higher than last year. Ex-date: 19th July 2024 Payment date: 9th August 2024 Dividend yield will be 2.1%, which is lower than the industry average of 3.7%. Sustainability & Growth Dividend is not covered by earnings (120% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 2 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 34% to bring the payout ratio under control. However, EPS has declined by 7.1% over the last 5 years so the company would need to reverse this trend. Reported Earnings • May 19
First quarter 2024 earnings released: NT$0.30 loss per share (vs NT$0.39 profit in 1Q 2023) First quarter 2024 results: NT$0.30 loss per share (down from NT$0.39 profit in 1Q 2023). Revenue: NT$97.1m (down 21% from 1Q 2023). Net loss: NT$10.2m (down 179% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Annuncio • May 03
Medimaging Integrated Solution Inc. to Report Q1, 2024 Results on May 10, 2024 Medimaging Integrated Solution Inc. announced that they will report Q1, 2024 results on May 10, 2024 Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: NT$2.20 (vs NT$2.20 in FY 2022) Full year 2023 results: EPS: NT$2.20 (up from NT$2.20 in FY 2022). Revenue: NT$537.1m (up 7.0% from FY 2022). Net income: NT$74.1m (up 5.8% from FY 2022). Profit margin: 14% (in line with FY 2022). New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: NT$3.14b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (4.1% increase in shares outstanding). Market cap is less than US$100m (NT$3.14b market cap, or US$99.6m). New Risk • Oct 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (4.1% increase in shares outstanding). New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (31% accrual ratio). New Risk • Aug 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). New Risk • Aug 16
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 31% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (31% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Reported Earnings • Aug 15
Second quarter 2023 earnings released: EPS: NT$0.86 (vs NT$0.53 in 2Q 2022) Second quarter 2023 results: EPS: NT$0.86 (up from NT$0.53 in 2Q 2022). Revenue: NT$142.4m (up 23% from 2Q 2022). Net income: NT$28.5m (up 74% from 2Q 2022). Profit margin: 20% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. New Risk • Jul 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to NT$122, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 35% over the past year. Upcoming Dividend • Jul 03
Upcoming dividend of NT$1.80 per share at 1.8% yield Eligible shareholders must have bought the stock before 10 July 2023. Payment date: 28 July 2023. Payout ratio is a comfortable 69% but the company is paying out more than the cash it is generating. Trailing yield: 1.8%. Lower than top quartile of Taiwanese dividend payers (5.5%). Lower than average of industry peers (3.3%). Reported Earnings • May 15
First quarter 2023 earnings released: EPS: NT$0.39 (vs NT$0.47 in 1Q 2022) First quarter 2023 results: EPS: NT$0.39 (down from NT$0.47 in 1Q 2022). Revenue: NT$122.3m (up 7.9% from 1Q 2022). Net income: NT$13.0m (down 8.2% from 1Q 2022). Profit margin: 11% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Buying Opportunity • Apr 14
Now 21% undervalued Over the last 90 days, the stock is up 44%. The fair value is estimated to be NT$134, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 31%. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: NT$2.20 (vs NT$2.30 in FY 2021) Full year 2022 results: EPS: NT$2.20. Revenue: NT$502.1m (up 3.3% from FY 2021). Net income: NT$70.0m (up 5.3% from FY 2021). Profit margin: 14% (in line with FY 2021). Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to NT$91.60, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 20x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment deteriorated over the past week After last week's 17% share price decline to NT$72.00, the stock trades at a trailing P/E ratio of 33.3x. Average forward P/E is 15x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 12% over the past year. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 15% share price decline to NT$82.40, the stock trades at a trailing P/E ratio of 38.1x. Average forward P/E is 15x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 55% over the past year. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improved over the past week After last week's 30% share price gain to NT$112, the stock trades at a trailing P/E ratio of 51.6x. Average forward P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 85% over the past year. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improved over the past week After last week's 18% share price gain to NT$64.40, the stock trades at a trailing P/E ratio of 29.8x. Average forward P/E is 18x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 16% over the past year. Upcoming Dividend • Jun 30
Upcoming dividend of NT$1.60 per share Eligible shareholders must have bought the stock before 07 July 2022. Payment date: 27 July 2022. Payout ratio is a comfortable 72% but the company is paying out more than the cash it is generating. Trailing yield: 2.8%. Lower than top quartile of Taiwanese dividend payers (6.4%). Lower than average of industry peers (3.4%). Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improved over the past week After last week's 23% share price gain to NT$58.10, the stock trades at a trailing P/E ratio of 26.9x. Average forward P/E is 17x in the Medical Equipment industry in Taiwan. Total returns to shareholders of 20% over the past year. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorated over the past week After last week's 18% share price decline to NT$49.70, the stock trades at a trailing P/E ratio of 20.8x. Average forward P/E is 18x in the Medical Equipment industry in Taiwan. Total loss to shareholders of 1.5% over the past year. Annuncio • Jun 01
Medimaging Integrated Solution Inc. has completed an IPO in the amount of TWD 128.1288 million. Medimaging Integrated Solution Inc. has completed an IPO in the amount of TWD 128.1288 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 627,000
Price\Range: TWD 46
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,108,000
Price\Range: TWD 47.1 Annuncio • Apr 14
Medimaging Integrated Solution Inc. has filed an IPO. Medimaging Integrated Solution Inc. has filed an IPO.
Security Name: Shares
Security Type: Common Stock
Price(maximum): TWD 55